SciBase - Vision to Value Creation
Vision
- Pioneering prediction and prevention in dermatology.
Mission
- Product: To develop unique, point-of-care platforms that combine AI (artificial intelligence) with our advanced EIS (electrical impedance spectroscopy) technology.
- Providers: To empower healthcare professionals to improve diagnostic accuracy, enable disease monitoring, and facilitate early intervention of skin cancer and skin disorders.
- Patients: Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection, and reducing overall healthcare costs.
Value Creation
- To become the global leader in non-invasive, high-precision skin assessment for cancer detection and skin barrier evaluation, capturing a significant share of a $1billion market while targeting a 75% gross margin.
Product portfolio
Nevisense is a non-invasivemedical device designed to assist healthcare professionals in the early detection and assessment of skin conditions, with a primary focus on melanoma, a potentially life-threatening form of skin cancer.
The Nevisense device utilizes a technology called electrical impedance spectroscopy to examine and analyze the electrical properties of skin lesions. By assessing these properties, Nevisense provides real-time data that can aid healthcare professionals in distinguishing between benign and potentially malignant skin lesions.
This technology enables healthcare providers to make more informed decisions regarding the need for further evaluation, biopsies, or treatments.
A five-year co-development project with the Royal Institute of Technology in Stockholm resulted in a single chip, an application-specific integrated circuit (ASIC) able to perform EIS measurements similar to Nevisense. Using the ASIC as a base, the Company developed Nevisense Go, a handheld version of Nevisense. Nevisense Go is a technological first – based on SciBase’s ASIC for EIS measurement and an embedded AI algorithm that performs analyses at the point-of-care. It promises to be a powerful platform for diagnostic barrier-related testing and potentially for other applications. Nevisense Go is initially sold for research purposes to both researchers and major pharmaceutical companies to assess the skin’s barrier function and is used or planned to be used in over 20 clinical studies.
The Company’s business model is built around a disposable electrode. Electrodes are sold on an on-going basis and each electrode can be used on one patient but can test up to 20 lesions or skin areas. Electrodes sales stands for the vast majority of sales and it is expected that electrodes sales will drive growth and by improving electrode margins, profitability.
The dashboard is a web-based visualization and analysis tool. Measurements can be exported from Nevisense or Nevisense Go and imported into the Dashboard.
Precision and Accuracy
The skin barrier has electrical properties that are affected by various medical conditions. By measuring the skin’s electrical impedance, it is possible to detect changes that may indicate certain diseases, such as melanoma.
SciBase’s Nevisense system uses a technology called Electrical Impedance Spectroscopy (EIS) to analyze the skin’s electrical properties. The technology involves applying a weak electrical current to the skin’s surface through proprietary Nevisense electrodes. Changes in these currents as they pass through the tissue are analyzed immediately after measurement using AI-based classification algorithms to assess the skin or classify the lesion’s risk level.
This enables the Nevisense system to detect subtle changes or abnormalities that may not be visible to the naked eye.